RESEARCH TRIANGLE PARK, N.C., May 27, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it is offering to sell $100 million of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of its common stock.
Help employers find you! Check out all the jobs and post your resume.
